Research delivers insight into the Erectile Dysfunction - Pipeline Review, H2 2016

Erectile Dysfunction - Pipeline Review, H2 2016 ​is a new market research publication announced by Reportstack. This report provides an overview of the Erectile Dysfunction pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Erectile Dysfunction, complete with analysis by stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Erectile Dysfunction and features dormant and discontinued projects.

To view the table of contents and know more details please visit Erectile Dysfunction - Pipeline Review, H2 2016

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape of Erectile Dysfunction
- The report reviews pipeline therapeutics for Erectile Dysfunction by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report reviews key players involved Erectile Dysfunction therapeutics and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Erectile Dysfunction

Reasons to buy

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Erectile Dysfunction pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned

Apricus Biosciences, Inc. Aytu BioScience, Inc. Biopharm GmbH Futura Medical Plc Hanmi Pharmaceuticals, Co. Ltd. Humanetics Corporation IntelGenx Corp. Ion Channel Innovations, LLC Mezzion Pharma Co. Ltd. Mitsubishi Tanabe Pharma Corporation Monosol Rx, LLC NAL Pharmaceuticals Ltd. Palatin Technologies, Inc. Pharmicell Co., Ltd. Sihuan Pharmaceutical Holdings Group Ltd. Suda Ltd Yungjin Pharm. Co., Ltd.

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###